Ion transporters are emerging targets of increasing importance to the pharmaceutical industry because of their relevance to a wide range of numerous indications of cardiovascular, metabolic, and inflammatory diseases. However, traditional iontransporter assay technologies using radioactive or fluorescent ligands and substrates or manual patch clamping suffer from several problems: limited sensitivity and robustness, significant numbers of false positives and false negatives, and cost. The authors describe a novel method for the measurement of ion transporters using cell-free electrophysiology based on the SURFE 2 R (surface electrogenic event reader) technology platform. The main advantages of the method described here are high sensitivity and simple handling. Material for assays is mainly a simple membrane preparation, which can be stored over weeks and months. Thus, the application of the method does not depend on a permanently running cell-culture lab. The application of the technology itself uses a bench-top system and chips loaded with membrane fragments. The SURFE 2 R technology was used to establish an Na + /Ca 2+ -exchanger assay. The assay performance, as judged by the Z′ value of 0.73 and the signal-to-background ratio of 7.6, suggests that this is a reliable and robust assay. The authors compared the technology with patch-clamp experiments: The measurement of activity of 17 different inhibitors and the determination of an IC 50 value indicated a good correlation between SURFE 2 R technology and patch clamp results. Using the SURFE 2 R technology, results were obtained with 20 times higher throughput and required less-qualified personnel compared with manual patch clamping. (Journal of Biomolecular Screening 2006:262-268) 
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Numerous disease states are related to dysfunctional ion transporters including obesity, diabetes, coronary heart diseases, hypertension, and CNS disorders such as epilepsy and depression. 1-4 A prominent example for drugs that exert their effect on transporter targets are inhibitors of the gastric H + /K + -ATPase (proton-pump inhibitors). Proton-pump inhibitors such as omeprazole act by inhibiting acid production in the stomach and are used in the treat-ment of ulcers and gastroesophageal reflux disease. 5 Drugs such as the blockbuster omeprazole have generated substantial revenues.
Drug-discovery technologies
Transporters are an emerging target family with enormous potential, offering scientific and economic opportunities. On the other hand, transporters are a difficult target class in terms of drugdiscovery technologies.
At present, preferred assay-detection technologies for iontransporter screening in primary and secondary screening are the following 6 :
safety issues associated with the radioactive screening technology are hurdles that hinder a broadened application. The number of fluorescent substrates and ligands for ion transporters is very limited, and in many cases, the screening results are confusing as scientists have to deal with false positives and false negatives. In addition, low signal-to-background ratios of most fluorescent ion-transporter assays render these assays unsuitable for general screening.
Even patch clamp is not a convincing alternative because of limited sensitivity, tremendous costs per data point, and low throughput. Automated patch clamp systems would have the potential to increase the throughput; nevertheless, the main remaining hurdles-price and sensitivity-are not overcome.
To make transporter proteins amenable to modern pharmaceutical drug screening and development, new technologies suitable for handling a broad range of proteins from this class are needed.
SURFE 2 R technology
Most transporters shift electrical charges while going through their transport cycle. This shift may originate either from the movement of charged substrates or from the movement of protein moieties carrying (partial) charges. This fact is the rationale behind a new technology called surface electrogenic event reader (SURFE 2 R), which detects the resulting transporter-related currents.
The SURFE 2 R technology is mainly based on transportercontaining membrane fragments or vesicles mechanically and electrically coupled to a gold-coated biochip: It is a "cell-free electrophysiology" method. The membrane fragments can be obtained from simple membrane preparations of transfected cells expressing the appropriate target. Standard centrifuges are sufficient for preparation. After preparation, the membrane fragments can be stored, and aliquots can be used over a period of several months.
These membrane fragments readily adsorb to a sensor chip surface that carries a modified lipid layer on a thin gold film (Fig. 1A) .
The membrane fragments form cavities that are able to maintain ion gradients across their membranes.
The transporters are activated by adding the appropriate substrate ( Fig. 1A) . Another means of transporter activation is to add an energy source such as ATP. After activating the transporters, ions (e.g., Na + ) or charged substrates are transported across the membrane. The resulting currents usually range from 100 pA to 10 nA. Because of the type of measurement, a stationary current is not necessary for detection of transporter activity; single electrically active steps are sufficient.
Sodium calcium exchanger
To evaluate the potential of cell-free electrophysiology as a drug-discovery technology for ion transporters, the human cardiac Na + /Ca 2+ exchanger (NCX1) was chosen as a model target. The cardiac Na + /Ca 2+ exchanger (NCX1), a plasma membrane antiporter, is almost certainly the major Ca 2+ extrusion mechanism in cardiac myocytes. 7, 8 Enhanced expression of NCX1 has recently been recognized as one of the molecular mechanisms that contribute to reduced Ca 2+ release, impaired contractility, and an increased risk of arrhythmias during the development of cardiac hypertrophy and failure. 9 The NCX1 has also been implicated in the mechanism cellular injury associated with ischemia and reperfusion. 10 Thus, the NCX1 plays a key role in the Ca 2+ homeostasis of cardiomyocytes and is discussed as a potential drug target. 11 In addition, all transporters of the NCX family may play a role with regard to potential side effects of drugs and could be used as an in vitro assay to characterize pharmacological profiles of new leads. 12
METHODS

Cell culture
Rapid generation of stably transfected cell lines was achieved using the Flp-In ® T-Rex ® expression system (Invitrogen, Carlsbad, CA). For this purpose, cDNA encoding for the human cardiac sodium calcium exchanger (NCX-1, i.e., SLC8A1 PDB-entry NM_021097) was cloned into the Flp-In ® T-Rex ® expression vector (Invitrogen) and subsequently transfected into HEK-293 cells (patch-clamp experiments) or into CHO cell line (SURFE 2 R experiments). For SURFE 2 R experiments membrane fragments of a stable NCX1 CHO cell line were used. The cells were kept in culture under standard conditions (37°C, air supplemented with 8% CO 2 ) in D-MEM (Invitrogen) supplemented with 10% fetal calf serum (Biochrom, Berlin, Germany), 50 mg/ml hygromycin (Invitrogen), and 10 mg/ml blasticidin (Invitrogen).
Cells were passed every 3 to 4 days using a trypsin/EDTA solution (Biochrom) to detach the cells. At least 12 to 24 h prior to 
R ONE biosensor setup
Transient ion transport currents were measured using a SURFE 2 R ONE biosensor system (IonGate Biosciences GmbH, Frankfurt am Main, Germany). The system consists of a flowanalysis device, a power supply, a standard PC, and an autosampler. The flow analysis device accommodates a sensor holder with an electromechanically operated 3/2-way valve, a built-in reference electrode, and a contact stick, both electrically connected to a current amplifier. Furthermore, it contains 3 buffer containers, each connected to its own external peristaltic pump, and a fluidic system with an electronic controller board, allowing PC-controlled concentration-jump experiments with up to 3 different solutions.
Biosensor measurements
For the determination of its activity, the NCX protein was treated consecutively with a preincubation, charging, and activating solution, and the current was measured when changing from charging to activating treatment. The replacement of the preincubation solution (sodium-containing, calcium-free buffer solution) with the charging solution (reduced sodium, calciumfree buffer solution) induces an Na + gradient across membranes harboring NCX protein. Thereafter, replacement of the solution by activating solution (Ca 2+ -containing solution) triggers the NCX activity. Subsequently replacing solutions in reverse order returns the sensor chip to its initial state.
After buffer containers A, B, and C of the biosensor system had been filled with activating buffer (30 mM HEPES/NMG, pH 7.4, 140 mM KCl, 4 mM MgCl 2 , 0.5 mM CaCl 2 ), charging buffer (30 mM HEPES/NMG, pH 7.4, 140 mM KCl, 4 mM MgCl 2 ), and preincubation buffer (30 mM HEPES/NMG, pH 7.4, 40 mM KCl, 100 mM NaCl, 4 mM MgCl 2 ), respectively, a dummy was mounted to the sensor holder, and the system was flushed with all buffers to remove air bubbles from the entire fluidic system. The dummy was then replaced by a standard glass-based sensor preloaded with NCX1-containing CHO membrane fragments (chemically modified gold surface of 3-mm diameter; IonGate Biosciences GmbH). Liquid transport through the fluidic system, including the sensor flow cell, was achieved by applying air pressure to the buffer containers.
Measurements were usually carried out at 200 mbar overpressure, resulting in a flow rate of about 300 µl/s -1 . For the determination of its activity, the membranes harboring NCX protein were treated consecutively by an incubation, charging, and activating solution. The replacement of the incubation solution by the charging solution induces an Na + gradient across membranes harboring NCX protein. Thereafter, replacement of the charging solu-tion by the activating solution triggers the NCX activity, and thus the induced electrical current was measured when changing from charging to activating solution. Subsequently replacing solutions in reverse order returns the sensor chip to its initial state. By means of the control software, a sequence was defined in which incubation buffer flowed over the sensor surface for 0.5 s, followed by charging buffer (2.0 s), activating buffer (2.0 s), charging buffer (2.0 s), and incubation buffer (2.0 s). During the whole sequence, the current response was digitized (2000 samples/s -1 ) and saved to data files. For dose-response experiments, inhibitors were dissolved in incubation, charging, and activating buffer, respectively. All chemicals were of analytical grade or better.
Patch-clamp recordings
The coverslips were tightly mounted in a recording chamber containing the low-calcium bath solution (see below) and placed on an inverted Zeiss microscope (Axiovert 200M; Göttingen, Germany). The recordings were performed at room temperature (20-25°C).
The recording electrode was filled with a solution containing 100 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 2.1 mM EGTA, 35 mM TEA-Cl, 4 mM Mg-ATP, 0.5 mM Na-GTP, 5.63 mM phosphocreatine, 30 mM Na/HEPES, and 3.5 U/ml creatine phosphokinase (pH = 7.4). The borosilicate glass electrodes typically had resistances between 2 and 4 MΩ. Series resistances ranged from 8 to 25 MΩ and were left uncompensated. The measurements were performed in the whole-cell mode of the patch clamp technique using an EPC-10 patch clamp amplifier (HEKA, Lambrecht, Germany). Signals were digitized at a frequency at least twice the filter cutoff frequency. Filter cutoff frequencies were 83.3 Hz and are quoted as the -3 dB attenuation frequency.
The cells were perfused using the DAD VC-8 pressure perfusion system (ALA Scientific, New York, NY). The perfusion pipette had a tip diameter of 200 µm and was placed approximately 150 µm away from the cell. The timing of the application was controlled by the Pulse software package (HEKA) that triggered the DAD VC-8.
During recording, cells were continuously superfused with a low-calcium bath solution (135 mM NMG-Cl, 5 mM MgCl 2 , 2 mM CaCl 2 , 4 mM EGTA, 30 mM Na/HEPES; pH = 7.4) using the DAD VC-8 perfusion pipette. To evoke currents carried by the NCX transporter, a high-calcium bath solution (139 mM NMG-Cl, 5 mM MgCl 2 , 2 mM CaCl 2 , 30 mM Na/HEPES; pH = 7.4) was puffed onto the cells for a period of 3 s. Two seconds of baseline was recorded before, and 3 s after, the application. To prevent sodium-dependent inactivation, 13 the stimulus was applied every 40 s. This stimulation protocol was repeated 4 times to verify the constancy of the NCX current over time. Subsequently, the lowcalcium solution containing the inhibitor was applied to the cell for 60 s.
The same stimulation protocol was then repeated 4 times using bath solutions containing the inhibitor. To monitor recovery, cells were perfused with a low-calcium solution, and NCX currents were evoked every 20 s by the standard stimulus protocol.
For each cell, the activity of only 1 compound at 1 concentration was evaluated. Therefore, NCX inhibitors were dissolved in both external solutions. All chemicals were of analytical grade or better.
Data analysis
To analyze NCX currents evoked in patch-clamp experiments, the mean amplitude of a 2-s time interval starting 1 s after stimulus onset was calculated using Pulse Fit software (HEKA).
The mean NCX current of the respective 4th stimulation under control conditions (I CTRL ) and with inhibitor in the bath (I INH ) was used for analysis. The inhibition of the NCX was quantified as the fraction I INH /I CTRL .
To analyze NCX currents generated in SURFE 2 R experiments, the peak current after activation with activating solution was calculated using the built-in software routine. The mean NCX-induced current (I CTRL ) of the last 3 of 8 stimulations (for complete removal of the contaminants of old solution) with and without applied inhibitor (I INH ) was used for analysis. The inhibition of NCX was quantified as the fraction I INH /I CTRL .
The mean of I INH /I CTRL at a given concentration was calculated and fitted with the Hill function: I INH /I CTRL = 1/(1 + (k/x)^h), where x corresponds to the concentration of inhibitor (in µM), h represents the Hill coefficient, and k is the concentration of inhibitor inducing 50% inhibition (IC 50 value). The fitting was computed using Igor Pro (WaveMetrics, Lake Oswego, OR) or Excel Fit (Microsoft, Unterschleissheim, Germany) with built-in routines. All errors are quoted as standard error of the mean (SEM).
RESULTS
Electrical signals of the human NCX
To evaluate SURFE 2 R technology, inhibitors of the human cardiac sodium calcium exchanger (NCX1) were compared using IonGate biosensors on an IonGate SURFE 2 R One bench-top setup (see Fig. 2 ) and standard patch-clamp electrophysiology. IC 50 values of several compounds were obtained and compared. Figure 1 shows preparation, working principle, and typical signals of NCX measurements in patch-clamp and SURFE 2 R measurements.
To measure the current carried by the NCX, patch-clamp measurements on single HEK cells were performed in the whole-cell mode. Under these conditions, the cytosol is substituted by the pipette solution within seconds. With the pipette solution containing high sodium concentrations (130 mM) and low extracellular sodium concentrations (30 mM), an outwardly directed sodium gradient was generated as the driving force for inwardly directed Ca 2+ transport. Thus, extracellular application of a calcium-containing solution (2 mM) at a holding potential of 0 mV resulted in an outward current displaying a tonic time response (Fig. 1D) . This stationary current is due to the activation of the sodium-calcium exchanger in the presence of Na + and Ca 2+ , leading to turnover conditions followed by net charge movement. This behavior is due to the countertransport stoichiometry of 3 Na + to 1 Ca 2+ . [14] [15] [16] It should be noted that under these conditions, the transporter is running in its reverse mode, 17, 18 in which Ca 2+ is transported into the cell and Na + out of the cell.
Assuming a turnover rate of 500 s -1 , [19] [20] [21] and an average current of~80 pA, the amount of NCX proteins per plasma membrane can be estimated to be 10 6 according to the equation I stat (Cs -1 )/turnover(s -1 )xe, where I stat is the stationary current and e the elementary charge 1.6 × 10 -19 C.
In SURFE 2 R experiments, the NCX-containing membrane fragments bound to the biosensors surface are exposed to a rapid Ca 2+ concentration jump, leading to a transient charging current. 90.5% ± 5.1%. The resulting dose-response curve is shown in Figure 3B . IC 50 values (n = 5) were recorded with application of the inhibitors' concentrations of 0.01, 0.1, 1, 5, and 10 µM. The value for 50% inhibition can be calculated to 0.9 ± 0.2 µM. The Hill coefficient could be calculated to 0.7 ± 0.03. Subsequent experiments in the absence of inhibitor A resulted in NCX peak currents with up to 100% of the amplitude of the initial signal, proving the inhibitors' reversibility.
Inhibition experiments using SURFE
In control experiments, the current could be diminished by reduction of the applied Ca 2+ jump and by application of the unspecific NCX1 blocker of Ni 2+ (5 mM). 22 Furthermore, membranes of cells not expressing NCX1 did not yield currents under similar experimental conditions. Figure 4A shows a typical NCX current inhibition experiment recorded with the patch-clamp technique. Under control conditions, Ca 2+ application generated a stationary outward current at a holding potential of 0 mV. Application of 10 µM inhibitor A reduced the NCX signal by 70% ± 11% (n = 5). However, application of inhibitor A did not alter the time response of the residual NCX current.
Inhibition experiments using patch clamp
In Figure 4B , the dose-response curve of inhibitor A is shown. The concentrations used in the experiments were 0.03 (n = 3), 0.3 (n = 4), 1 (n = 5), 10 (n = 5), and 30 µM (n = 3), respectively. The IC 50 value calculated was 1.4 ± 0.4 µM, with a Hill coefficient of 0.43 ± 0.03.
To investigate if other membrane conductances were activated by application of high calcium concentrations, measurements with HEK cells that had not been treated with doxycycline were performed. In 5 untreated HEK cells, zero current was measured after application of external Ca 2+ (data not shown). A concentration of 1 mM Ni 2+ reversibly blocked NCX current by 100% (n = 5; data not shown). Figure 5 illustrates the correlation of inhibition data on the SURFE 2 R versus inhibition data of patch-clamp measurements. The efficiency of inhibition of 10 µM of 17 inhibitors (n = 3-5) was calculated according to the procedure shown previously. The inhibitory effect of these inhibitors ranged from 10% to 100%, allowing for a good assignment of a correlation. Under both experimental conditions, NCX inhibition could be measured with similar inhibitory effects. Thus, the inhibitory effect of 10 µM compound correlates very well with an R 2 of 0.8, indicating a high validity of the SURFE 2 R data.
Correlation of inhibition experiments
As indicated by the point of intersection on the ordinate, SURFE 2 R measurements showed a higher sensitivity to inhibition than patch-clamp measurements did, which are considered to be the gold standard in this respect, as indicated previously.
DISCUSSION
The effect of inhibitors on the human sodium-calcium exchanger was investigated using IonGate's SURFE 2 R technology. This cell-free technology allows fast and efficient measurements with highly comparable results in a setup that allows automation and thus screening of focused compound libraries. The obtained inhibitory effects were monitored in patch-clamp experiments.
Increased signal-to-noise ratio
It seems clear that (at least in case of the NCX1) SURFE 2 R signals yield up to 10 times higher amplitudes than those from patchclamp recordings (Fig. 1C, D) . Moreover, a better signal-to-noise ratio is obtained (Fig. 3A) . The most obvious reason for these 2 effects is the large amount of membranes bound to the biosensor chip containing the target molecules. Thus, the biosensor is able to collect signals from a higher number of ion transporters. An important prerequisite for a good signal-to-noise ratio is a tight electrical coupling of the NCX protein to the gold surface. The most important cause for the higher sensitivity, however, may be for kinetic reasons: Its basis is the triggered release of transporter activity. The electrogenic step of all proteins is started in a synchronized fashion within 5 to 10 ms activation time. This technological feature not only increases the signal-to-noise ratio but also allows investigation of rate-limiting steps in the transport cycle of transporters and enables mode-of-action approaches in the drug-discovery process.
Another striking observation is the shifted IC 50 , with higher sensitivity in SURFE 2 R experiments ( Fig. 5) . An obvious explanation for this effect can be found in the different realization of patchclamp and SURFE 2 R experiments. Although the signals generated with the sensors in the SURFE 2 R are stable for long time periods, the patch-clamp experiments have to be performed as quickly as possible because of the limited stability of the patch and rundown of the observed currents during the experiment. Thus, equilibration of the cell with the given inhibitor concentration may not be complete in the patch-clamp experiments, leading to an underestimation of inhibitor potency. In contrast to this, in SURFE 2 R experiments, inhibitor-containing solutions were always applied until the full equilibration was reached. Furthermore, this equilibration of inhibitor with cells in the patch-clamp experiment appeared to be slower than in the SURFE 2 R experiment. This can be accounted for by the different structure of the protein-containing membranes or small membrane fragments, in the case of the SURFE 2 R and whole cells, and a higher capacity for buffering an inhibitor in the case of patch-clamp experiments.
A method with high time resolution surely facilitates investigation of these kinds of transporters: the SURFE 2 R enables immanent pre-steady state experiments, whereas patch clamping can be performed with only low throughput (via highly sophisticated rapid solution exchange or voltage-jump experiments). An even stronger argument is the advantage of the SURFE 2 R technology when investigating transporters that do not generate net-electrical charge movement, such as the gastric H + /K + -ATPase.
Impact on state-of-the-art technology
The pharmacological characterization of new leads as well as screening of large compound libraries using fluorescence assays with Ca 2+ -sensitive fluorescence dyes typically gives results that are impaired by the finding of false-positive hits. To evaluate the activity of these compounds, a secondary assay that detects protein function more reliably must be established. In the case of NCX, currents that are mediated by the protein are a good measure of its activity. As a gold standard for such experiments, the patch-clamp technology is routinely applied in many electrophysiology laboratories. Although the technology is known for its high sensitivity, patch-clamp measurements of heterologously expressed transporters are far from a routine application. Given the low signal-to-noise ratio in combination with fast rundown, a large number of experiments are required for a reliable measurement of substance activity. Thus, throughput is low compared with measuring ion channels. The SURFE 2 R technology used in the study has proven to be a robust method for hit confirmation and validation in NCX screening campaigns as well as in the selectivity profiling of lead structures. This new technology is particularly suited to directly measure the activity of electrogenic transporters and ion pumps.
Compared to patch clamping, the throughput is higher by a factor of 20, and the operation of the desktop device requires far less skill than manual patch clamping. The correlation of the generated data shows that within the investigated group of compounds, the correlation between patch clamp and SURFE 2 R data is sufficient, showing R 2 = 0.81.
In the course of a drug-discovery project that employs patch clamping of cells expressing the target protein, cell culture and cell quality are always critical aspects. Stable cell lines might lose expression of the target protein, or the quality of the cells might become insufficient for stable whole-cell measurements. In addition, cell culture is very time consuming and cost intensive. For SURFE 2 R experiments in the present study, cells were produced in a batch procedure, and generated plasma membrane fragments were stored for months without loss of quality. Hence, the SURFE 2 R technology does not require manpower or investment for materials involved with cell culture during the entire drugdiscovery project. Thus, the SURFE 2 R technology substantially reduces overall costs per data point compared with manual patch clamping. Further refinement of the SURFE 2 R bench-top technology and assay development for different proteins at IonGate will give rise to higher throughput combined with lower costs. With the applicability of the technology further optimized, the SURFE 2 R technology will become the preferred technology for transporter research. 
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